November 2024 in “EMJ Dermatology” In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.
42 citations
,
January 2021 in “Journal of Clinical Medicine” This review discusses advancements in the use of microneedle arrays and nanoparticles for transdermal delivery of therapeutics, noting challenges in overcoming the skin barrier and summarizing recent clinical trial achievements in areas like cancer therapy and gene therapy.
3 citations
,
January 2022 in “Scientific Reports” This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.
December 2025 in “Clinical & Experimental Dermatology and Therapies” This study reported that Cosmerna ARI significantly improved androgenetic alopecia in Europeans over a 6-month period compared to a placebo, according to a double-blind, randomized, placebo-controlled clinical trial.
August 2024 in “Cosmetics” This review discusses genetic and pharmacogenetic insights, along with RNA interference technologies, for developing personalized therapies for androgenetic alopecia, yet presents no new clinical results.
